Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures
Enrolling by invitation · Early Phase 1 · Has a placebo group
Conditions studied: Longevity, Quality of Life, Mood, Inflammation, Immune Health, Pain Management, Weight Management, Alertness
In brief
The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.
Key facts
- Study ID
- NCT07092605
- Run by
- AgelessRx
- People needed
- 150
- Starts
- 2024-11-01
- Expected to finish
- 2025-12-01
- Last updated by the study team
- 2025-07-30
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- New or existing AgelessRx patient
- Adults (aged 18-65)
- Any sex
- Any ethnicity
- BMI ≥ 20 kg/m\^2
- Interest in taking microdoses of semaglutide for health and longevity improvement with no intent to seek weight loss improvement.
You may not qualify if…
- Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s)
- History of bariatric surgery
- Use of other weight-loss medications currently or within the past 6 months
- Contraindications to semaglutide
- Significant psychiatric illness that may affect participation
- Pregnant or breastfeeding individuals
Where it is running
- AgelessRx — Ann Arbor, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.